References
- Finkelstein Y, Kushnir A, Raikhlin-Eisenkraft B, Taitelman U. Antidotal therapy of severe acute organophosphate poisoning: A multihospital study. Neurotoxicol Teratol 1989; 11: 593–596
- Engelhard H, Erdmann W D. Ein neuer Reaktivator fuer durch Alkylphosphat gehemmte Acetylcholinesterase. Klin Wochenschr 1963; 41: 525–527
- Erdmann W D, Clarmann M V. Ein neuer Esterase-Reaktivator fuer die Behandlung von Vergiftungen mit Alkylphosphaten. Deut Med Wochenschr 1963; 88: 2201–2206
- Sidell F R, Groff W A. Toxogonin: blood levels and side effects after intramuscular administration in man. J Pharm Sci 1970; 59: 793–797
- Alioth-Streichenberg C M, Bodmer D M, Waser P G. Pharmacokinetics and pharmacodynamics of obidoxime in sarin-poisoned rats. Toxicol Appl Pharmacol 1991; 108: 509–519
- Tamaron. Hazardous Substances Data Bank (HSDB). National Library of Medicine, Micromedex, Inc., Denver, Colorado 1991
- Simon G A, Tirosh M S, Edery H. Administration of obidoxime tablets to man. Plasma levels and side reactions. Arch Toxicol 1976; 36: 83–88
- Erdmann W D, Okonek S. Ueber die gastrointestinale Resorption des Esterasereaktivators Obidoxim und die Moeglichkeiten einer Resorptionsforderung. Arch Toxicol 1969; 24: 91–101
- Milosevic M, Vojodic V, Terzic M. Blood concentration of N,N′-trimethylenebis (pyridinium-4-aldoxime) (TMB-4) and N,N′-oxydimethlene bis (pyridinium-4-aldoxime) (toxogonin) after intravenous and intramuscular administration in the dog. Biochem Pharmacol 1967; 16: 2435–2438
- Sidell F R, Groff W A, Kaminskis A. Toxogonin and pralidoxime: kinetic comparison after intravenous administration to man. J Pharm Sci 1972; 61: 1765–1769
- Willems J L, Langerberg J P, Verstraete A G, et al. Plasma concentration of pralidoxime methylsulphate in organophosphorus poisoned patients. Arch Toxicol 1992; 66: 260–266
- Schoene K, Koenig H, Oldiges H, Kruegel M. Pharmacokinetics and efficacies of obidoxime and atropine in paraoxon poisoning. Arch Toxicol 1988; 61: 387–391
- Erdmann W D, Bosse I, Franke P. Zur Resorption und Ausscheidung von Toxogonin nach intramuskularer Injektion am Menschen. Deut Med Wochenschr 1965; 90: 1436–1438
- Sundwahl A. Minimum concentrations of N-methylpyridinium-2aldoxime methane sulphonate (P2S) which reverse neuromuscular block. Biochem Pharmacol 1961; 8: 413–417